The global cyclin dependent kinase (CDK) inhibitors market is anticipated to grow at a significant CAGR during the forecast period. The market is primarily driven by the rising incidence of cancers across the globe. Resultantly, it has increased exposure to several risk factors such as carcinogens, sedentary lifestyles, substance abuse, pollution, and others. Additionally, the growing geriatric population is another major factor that is providing various growth opportunities for the CDK inhibitors market to expand. According to the World Health Organization, the number of people aged 60 and up is expected to rise exponentially over the decade, which in turn will propel the incidence of diseases such as hypertension, diabetes, and others.
Get Free Sample link @ https://www.omrglobal.com/request-sample/cyclin-dependent-kinase-cdk-inhibitors-market
The COVID-19 pandemic has impacted the global economy due to a slowdown in the manufacturing of various industries. As per the studies published by the WHO and National Library of Medicine, the COVID-19 (SARS-CoV-2) increased the phosphorylation of CDK2 which affects its activities and subsequently leads to cell cycle arrest, further restricting the use of CDK inhibitors for the patient diagnosed with COVID-19 infection. Thus, such factors have restrained the growth of the market during the pandemic.
A full report of Global Cyclin Dependent Kinase (CDK) Inhibitors Market available @ https://www.omrglobal.com/industry-reports/cyclin-dependent-kinase-cdk-inhibitors-market
- Market Coverage
- Market number available for – 2022-2028
- Base year- 2021
- Forecast period- 2022-2028
- Segment Covered- By Source, By Product Type, By Applications
- Competitive Landscape- Archer Daniels Midland Co., Ingredion Inc., Kerry Group Plc, Cargill Inc., and others
Market Segmentation
Global Cyclin Dependent Kinase (CDK) Inhibitor Market by Type
- Specific Inhibitors
- Non-Specific Inhibitors (Broad Range Inhibitors)
- Multiple Target Inhibitors
Global Cyclin Dependent Kinase (CDK) Inhibitor Market by Administration
- Nasal
- Oral
- Intravenous
- Intramuscular
Global Cyclin Dependent Kinase (CDK) Inhibitor Market by Application
- Breast Cancer
- Lymphoma
- Multiple Myeloma
- Ovarian Cancer
- Others (Cystic Fibrosis)
Regional Analysis
- North America
- United States
- Canada
- Europe
- UK
- Germany
- Italy
- Spain
- France
- Rest of Europe
- Asia-Pacific
- China
- India
- Japan
- South Korea
- Rest of Asia-Pacific
- Rest of the World
Company Profiles
- Novartis Pharma AG
- Onconova Therapeutics, Inc.
- Pfizer Inc.
- Teijin Ltd.
- ViroStatics srl
- Xuanzhu Biopharmaceutical Co., Ltd.
The Report Covers
- Market value data analysis of 2021 and forecast to 2028.
- Annualized market revenues ($ million) for each market segment.
- Country-wise analysis of major geographical regions.
- Key companies operating in the global cyclin dependent kinase (CDK) inhibitors market. Based on the availability of data, information related to new product launches, and relevant news is also available in the report.
- Analysis of business strategies by identifying the key market segments positioned for strong growth in the future.
- Analysis of market-entry and market expansion strategies.
- Competitive strategies by identifying ‘who-stands-where’ in the market.
For More Customized Data, Request for Report Customization @ https://www.omrglobal.com/report-customization/cyclin-dependent-kinase-cdk-inhibitors-market
About Orion Market Research
Orion Market Research (OMR) is a market research and consulting company known for its crisp and concise reports. The company is equipped with an experienced team of analysts and consultants. OMR offers quality syndicated research reports, customized research reports, consulting and other research-based services.
Media Contact:
Company Name: Orion Market Research
Contact Person: Mr. Anurag Tiwari
Email: info@omrglobal.com
Contact no: +91 780-304-0404
